Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AEGLEA BIOTHERAPEUTICS, INC.

(AGLE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/24/2022 01/25/2022 01/26/2022 01/27/2022 01/28/2022 Date
4.47(c) 4.36(c) 4.2(c) 3.99(c) 4.04 Last
201 223 80 539 181 320 187 974 206 719 Volume
+3.47% -2.46% -3.67% -5.00% +1.25% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 16,9 M - -
Net income 2021 -66,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,00x
Yield 2021 -
Sales 2022 2,12 M - -
Net income 2022 -101 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,16x
Yield 2022 -
Capitalization 197 M 197 M -
Capi. / Sales 2021 11,6x
Capi. / Sales 2022 92,8x
Nbr of Employees 90
Free-Float 98,4%
More Financials
Company
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The CompanyÔÇÖs product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine... 
More about the company
Ratings of Aeglea BioTherapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about AEGLEA BIOTHERAPEUTICS, INC.
01/25Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase..
PR
01/10AEGLEA BIOTHERAPEUTICS : 40th Annual J.P. Morgan Health Care Conference
PU
01/05AEGLEA BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statement..
AQ
01/05Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022
PR
2021Aeglea BioTherapeutics' Pegzilarginase Study in Patients With Arginase 1 Deficiency Ach..
MT
2021Top Premarket Decliners
MT
2021AEGLEA BIOTHERAPEUTICS : Announces Achievement of Primary Endpoint in Phase 3 Study of Peg..
PU
2021AEGLEA BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statement..
AQ
2021Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pe..
PR
2021Aeglea BioTherapeutics, Inc. Announces Achievement of Primary Endpoint in Phase 3 Study..
CI
2021AEGLEA BIOTHERAPEUTICS : PEACE Phase 3 Topline Data Webcast
PU
2021Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Peg..
PR
2021AEGLEA BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors
PR
2021Aeglea BioTherapeutics, Inc. Appoints Hunter Smith as A Class I Director and as A Membe..
CI
More news
News in other languages on AEGLEA BIOTHERAPEUTICS, INC.
2021L'étude sur la pegzilarginase menée par Aeglea BioTherapeutics auprès de patients souff..
2021Earnings Flash (AGLE) AEGLEA BIOTHERAPEUTICS affiche un chiffre d'affaires de 1,4 milli..
2021Earnings Flash (AGLE) AEGLEA BIOTHERAPEUTICS affiche un chiffre d'affaires de 13,7 mill..
2021La pegzilarginase d'Aeglea BioTherapeutics citée comme traitement potentiel du déficit ..
2021Aeglea BioTherapeutics nomme Jonathan Alspaugh au poste de directeur financier
More news
Analyst Recommendations on AEGLEA BIOTHERAPEUTICS, INC.
More recommendations
Chart AEGLEA BIOTHERAPEUTICS, INC.
Duration : Period :
Aeglea BioTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AEGLEA BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 3,99 $
Average target price 12,43 $
Spread / Average Target 211%
EPS Revisions
Managers and Directors
Anthony G. Quinn President, Chief Executive Officer & Director
Jonathan D. Alspaugh Chief Financial Officer
Russell J. Cox Chairman
Leslie Sloan Senior Vice President-Operations
Armen B. Shanafelt Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AEGLEA BIOTHERAPEUTICS, INC.-16.00%197
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325